Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Hepatitis B Virus (HBV) Capsid Inhibitors Market Size Forecast: How Big Could The Market Get By 2030?
The hepatitis b virus (hbv) capsid inhibitors market size has experienced significant expansion in recent years. It is projected to escalate from $0.52 billion in 2025 to $0.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. The historical growth observed in this sector was driven by factors including the worldwide impact of chronic hepatitis B infection, the deficiencies of current antiviral treatments, the initial clinical verification of capsid inhibitors, augmented funding for virology research, and increasing engagement in pharmaceutical pipeline development.
The hepatitis b virus (hbv) capsid inhibitors market size is projected to experience rapid expansion over the coming years. Its valuation is anticipated to reach $0.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.4%. This projected growth during the forecast period is attributable to several factors, including the increasing use of combination regimens with immunotherapies, a surge in investment directed towards curative hbv treatments, a rise in regulatory approvals for innovative antivirals, the expansion of global screening initiatives, and advancements in next-generation capsid inhibitors. Key developments expected within this period involve an escalating focus on functional cure strategies for hbv, the increasing creation of capsid assembly modulators, a growing adoption of combination therapy approaches, the expansion of late-stage clinical pipelines, and improved targeting of viral replication pathways.
Get A Free Sample Report With In-Depth Market Insights:
Hepatitis B Virus (HBV) Capsid Inhibitors Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The expanding occurrence of hepatitis B virus infections is anticipated to boost the hepatitis B virus (HBV) capsid inhibitors market in the future. Hepatitis B Virus (HBV) infections are liver ailments stemming from the hepatitis B virus, capable of causing both short-term and long-term illnesses. These infections spread via exposure to contaminated blood or bodily fluids, potentially leading to severe issues like liver cirrhosis or liver cancer. The rising incidence of Hepatitis B Virus (HBV) infections is primarily attributable to insufficient vaccination rates, leaving many unprotected and facilitating the virus’s transmission through contact with infected blood or bodily fluids. Hepatitis B virus (HBV) capsid inhibitors combat hepatitis B virus (HBV) infections by interfering with the viral capsid’s formation and assembly, which in turn halts viral replication and curtails the infection’s dissemination throughout the body. For example, a report from the World Health Organization (WHO), a Switzerland-based intergovernmental body, in April 2024, indicated that by the close of 2022, merely 13% of those with chronic hepatitis B had been diagnosed, and roughly 3% (7 million) had undergone antiviral therapy. Regarding hepatitis C, 36% of affected persons were diagnosed, with 20% (12.5 million) getting curative treatment. These statistics fall significantly short of the worldwide goal to treat 80% of individuals with chronic hepatitis B and C by 2030. Consequently, the rising prevalence of hepatitis B virus infections is fueling the expansion of the hepatitis B virus (HBV) capsid inhibitors market.
Hepatitis B Virus (HBV) Capsid Inhibitors Market Segment Outlook: Which Categories Are Growing Fastest?
The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –
1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types
2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)
2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators
3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors
Hepatitis B Virus (HBV) Capsid Inhibitors Market Innovation Trends Shaping Future Development
Leading companies within the hepatitis B virus (HBV) capsid inhibitors market are focusing on innovations, including oral small molecule capsid assembly modulators, to enhance antiviral effectiveness, improve patient adherence, and achieve sustained viral suppression. These oral small-molecule capsid assembly modulators are orally administered antiviral agents designed to disrupt the assembly of the hepatitis B virus (HBV) capsid, thereby blocking its replication and reducing viral activity in the body. For example, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, partnered with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to initiate a clinical trial. This trial aims to evaluate innovative treatment candidates for chronic hepatitis B (CHB), leveraging Aligos’s advanced capsid assembly modulator technology to boost antiviral efficacy and accelerate the development of next-generation HBV therapies. This launch signifies a key progression in Aligos’s objective to develop effective and potentially curative treatments for patients living with chronic hepatitis B.
Hepatitis B Virus (HBV) Capsid Inhibitors Market Leading Companies And Competitive Benchmarking
Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.
View The Full Hepatitis B Virus (HBV) Capsid Inhibitors Market Report:
Hepatitis B Virus (HBV) Capsid Inhibitors Market Regional Outlook: Where Is Opportunity Concentrated?
Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model